ArticlePediatric nephrology (Berlin, Germany)2022
SARS-CoV-2 infection in children with chronic kidney disease.
Article in Pediatric nephrology (Berlin, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 34 citations in OpenAlex.
- Vaccination in Children with Chronic Kidney Disease: Current Status and Perspectives.Vaccines · 2025Review
- Clinical characteristics of children with idiopathic nephrotic syndrome infected with SARS-CoV-2: a single-center retrospective cohort study.BMC pediatrics · 2025Article
- IPNA clinical practice recommendations on care of pediatric patients with pre-existing kidney disease during seasonal outbreak of COVID-19.Pediatric nephrology (Berlin, Germany) · 2025Review
- Humoral and cellular immunogenicity of a fourth dose BNT162b2 in children with chronic kidney diseases.Clinical kidney journal · 2025Article
- COVID-19 Associated Worry and Emotional Distress in Youth and Young Adults with Chronic Kidney Disease.Annals of pediatrics · 2025Article
- Safety of BNT162b2 mRNA COVID-19 vaccine in children with chronic kidney disease: a national population study from South Korea.Pediatric nephrology (Berlin, Germany) · 2024Article
- Humoral and Cellular Immunogenicity of 3 Doses of BNT162b2 in Children With Kidney Diseases.Kidney international reports · 2023Article
- COVID-19 in immunocompromised children and adolescents.Clinical and experimental pediatrics · 2023Article
- Epidemiology, severity, and risk of SARS-CoV-2-related relapse in children and young adults affected by idiopathic nephrotic syndrome: a retrospective observational cohort study.Pediatric nephrology (Berlin, Germany) · 2023Observational
- Relapse rate in children with nephrotic syndrome during the SARS-CoV-2 pandemic.Pediatric nephrology (Berlin, Germany) · 2023Article
- COVID-19 Infection in Chronic Kidney Disease Patients in Bulgaria: Risk Factors for Death and Acute Kidney Injury.Journal of personalized medicine · 2022Article
- Late-onset hypertension in a child with growth retardation: Answers.Pediatric nephrology (Berlin, Germany) · 2022Article
- Anti-factor H antibody associated hemolytic uremic syndrome following SARS-CoV-2 infection.Pediatric nephrology (Berlin, Germany) · 2022Article
- SARS-CoV-2 infection in children with nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2022Article
- Response to Krishnasamy et al.Pediatric nephrology (Berlin, Germany) · 2022Article
- Intrinsic Kidney Pathology Following COVID-19 Infection in Children and Adolescents: A Systematic Review.Children (Basel, Switzerland) · 2021Review
- The challenges of the pandemic and the vaccination against covid-19 in pediatric patients with kidney disease.Jornal brasileiro de nefrologiaArticle
Corrections and comments
- Commented on by
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundInformation on the course of SARS-CoV-2 infection in children with chronic kidney disease (CKD) is limited.
methodsWe retrospectively reviewed the presentation and outcomes of SARS-CoV-2 infection in patients with CKD followed at any of the four pediatric nephrology centers in New Delhi from April 2020 to June 2021. Outcomes, including cardiopulmonary and renal complications, were reported in relation to underlying disease category and illness severity at presentation.
resultsUnderlying illness in 88 patients included nephrotic syndrome (50%), other CKD stages 1-4 (18.2%), CKD 5D (17%), and CKD 5T (14.8%). Thirty-two of 61 patients with symptomatic COVID-19 and 9/27 asymptomatic patients were admitted for median 10 (interquartile range 7-15) days. Seventeen (19.3%) patients developed moderate or severe COVID-19. Systemic complications, observed in 30 (34.1%), included acute kidney injury (AKI, 34.2%), COVID-19 pneumonia (15.9%), unrelated pulmonary disease (2.3%), and shock (4.5%). Nineteen (21.6%) had severe complications (AKI stage 2-3, encephalopathy, respiratory failure, shock). Eight (11%) of twelve (16.4%) patients with severe AKI required dialysis. Three (3.4%) patients, two with steroid-resistant nephrotic syndrome in relapse and one with CKD 1-4, died due to respiratory failure. Univariate logistic regression indicated that patients presenting with nephrotic syndrome in relapse or moderate to severe COVID-19 were at risk of AKI (respective odds ratio, 95%CI: 3.62, 1.01-12.99; 4.58, 1.06-19.86) and/or severe complications (respective odds ratio, 95%CI: 5.92, 1.99-17.66; 61.2, 6.99-536.01).
conclusionsChildren with CKD presenting with moderate-to-severe COVID-19 or in nephrotic syndrome relapse are at risk of severe complications, including severe AKI and mortality. A higher resolution version of the Graphical abstract is available as Supplementary information.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.